Regional resistance surveillance program results for 12 Asia-Pacific nations (2011)

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5721-5726

  Mendes, Rodrigo E ^a   Mendoza, Myrna ^b   Banga Singh, Kirnpal K ^c   Castanheira, Mariana ^a   Bell, Jan M ^d   Turnidge, John D ^d   Lin, Stephen S F ^e   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b PHILIPPINE GENERAL HOSPITAL   (Philippines)

^c SCHOOL OF HEALTH SCIENCES   (Malaysia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; DOXYCYCLINE; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SOUTH KOREA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS MITIS; STREPTOCOCCUS ORALIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SANGUINIS; TAIWAN;

ANTI-BACTERIAL AGENTS; ASIA; AUSTRALIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; NEW ZEALAND; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84885904335     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01121-13     Document Type: Article

References (19)

1. Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. 2010. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J. Infect. 60:440-451.
4. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. 2011. Carbapenems: past, present, and future. Antimicrob. Agents Chemother. 55:4943-4960.
5. Bell JM, Turnidge JD, Ballow CH, Jones RN. 2003. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J. Antimicrob. Chemother. 51:339-345.
6. Hawser SP, Bouchillon SK, Hackel M, Chen M, Kim EC. 2012. Trending 7 years of in vitro activity of tigecycline and comparators against Grampositive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010. Int. J. Antimicrob. Agents 39:490-495.
7. Woodford N, Livermore DM. 2009. Infections caused by Gram-positive bacteria: a review of the global challenge. J. Infect. 59(Suppl 1):S4 -S16.
8. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597-602.
9. Bonnet R. 2004. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1-14.
10. Rice LB. 2012. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Mayo Clin. Proc. 87:198-208.
11. EUCAST. 2013. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. http://www.eucast.org/clinical- breakpoints/. Accessed 2 January 2013.
12. Pfizer Inc. 2012. Tygacil package insert. Pfizer Inc, New York, NY. http://labeling.pfizer.com/showlabeling.aspx?id-491. Accessed January 2013.
13. Mendes RE, Jones RN, Deshpande LM, Ross JE, Sader HS. 2009. Daptomycin activity tested against linezolid-nonsusceptible grampositive clinical isolates. Microb. Drug Resist. 15:245-249.
14. Rolain JM, Parola P, Cornaglia G. 2010. New Delhi metallo-betalactamase (NDM-1): towards a new pandemia? Clin. Microbiol. Infect. 16:1699-1701.
15. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. 2008. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallo-betalactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 52: 570-573.
16. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY Antimicrobial Surveillance Programme (2007-09). J. Antimicrob. Chemother. 66:1409-1411.
17. Jones RN, Mendes RE, Castanheira M, Hu B, Ni Y, Wang Y. Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011). Diagn. Microbiol. Infect. Dis., in press.
18. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. 2013. An international activity and spectrum analysis of linezolid: ZAAPS program results for 2011. Diagn. Microbiol. Infect. Dis. 76:206-213.
19. Gould IM. 2011. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 66(Suppl 4):iv17-iv21. doi:10.1093/jac/dkr073.